This company is no longer active
DFFN Stock Overview
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Diffusion Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.59 |
| 52 Week High | US$14.37 |
| 52 Week Low | US$4.14 |
| Beta | 1.76 |
| 1 Month Change | 64.82% |
| 3 Month Change | 26.82% |
| 1 Year Change | -26.88% |
| 3 Year Change | -91.04% |
| 5 Year Change | -98.26% |
| Change since IPO | -99.66% |
Recent News & Updates
Recent updates
Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02
Aug 12We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully
Feb 25
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth
Nov 12We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate
Jun 25Diffusion Pharmaceuticals EPS misses by $0.02
May 10We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation
Nov 23Shareholder Returns
| DFFN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 44.2% | 0.4% | 1.0% |
| 1Y | -26.9% | 0.9% | 21.9% |
Return vs Industry: DFFN underperformed the US Biotechs industry which returned 3.5% over the past year.
Return vs Market: DFFN underperformed the US Market which returned 1% over the past year.
Price Volatility
| DFFN volatility | |
|---|---|
| DFFN Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DFFN's share price has been volatile over the past 3 months.
Volatility Over Time: DFFN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 13 | Bob Cobuzzi | www.diffusionpharma.com |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc. Fundamentals Summary
| DFFN fundamental statistics | |
|---|---|
| Market cap | US$13.47m |
| Earnings (TTM) | -US$13.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs DFFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DFFN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.08m |
| Earnings | -US$13.08m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DFFN perform over the long term?
See historical performance and comparison